Fig. 2

Sets of alterations shared across many tumors. a Top additive “and/or” alterations were determined by maximizing the number of unique tumors containing one or more alterations (from left to right; i.e., tumors with gene 1 and/or gene 2, etc.). Overlap across variants was determined by four broad categories (Gene, Type, Variant, Missense SNVs/non-frameshift (fs) indels). b Neoantigen prediction strategy incorporating the number of peptides processed and predicted to bind to specific HLA subtypes